Radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma: A systematic review and meta-analysis

Figure 3 Relative risks and 95%CIs for risk of radiofrequency ablation rate of hepatocellular carcinoma comparing combined therapy (radiofrequency ablation/transarterial chemoembolization) with radiofrequency ablation alone. The overall estimates were obtained by using a random-effects model. The dots indicate the RRs. The size of the shaded square is proportional to the weight of each study. The horizontal lines represent 95%CIs. The diamond data markers indicate the RRs. RRs: Relative risks.